
RKLB · Nasdaq
Consensus is Buy across 11 analysts, with a stated mean price target of $120. No low or high target is available, so the evidence cannot establish where targets cluster or how wide the target spread is, nor identify the most or least bullish analyst. The supplied material also contains no attributable analyst actions or target revisions during the past week, leaving revision direction unconfirmed. The substantive disagreement visible in the research is between growth and execution optimism—supported by revenue rising to $0.6 billion, NASA missions and the $397 million contract—and concerns about valuation, continuing losses, dilution, Iridium-related risk and the Neutron timetable. Those themes explain the debate but not a documented analyst target range.